TY - JOUR T1 - Recommendations for HER2 testing in the UK JF - Journal of Clinical Pathology JO - J Clin Pathol SP - 890 LP - 892 DO - 10.1136/jcp.53.12.890 VL - 53 IS - 12 AU - I O Ellis AU - M Dowsett AU - J Bartlett AU - R Walker AU - T Cooke AU - W Gullick AU - B Gusterson AU - E Mallon AU - P Barrett Lee Y1 - 2000/12/01 UR - http://jcp.bmj.com/content/53/12/890.abstract N2 - Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin®), which has recently been licensed for the treatment of metastatic disease. This necessitates a test based on archival material. The preferred analyses are immunohistochemistry with fluorescent in situ hybridisation (FISH) as a follow up test for ambiguous results. Guidelines have been developed for standardised, well controlled procedures for the provision of reliable results. A group of three reference laboratories has been established to provide advice, quality assurance, and materials, where needed. ER -